开拓药业-B年报 2023

Stock Code: 9939(Incorporated in the Cayman Islands with limited liability) CONTENTS Independent Auditor’s Report122Consolidated Statement of Comprehensive Income133Consolidated Statement of Financial Position134Consolidated Statement of Changes in Equity136Consolidated Statement of Cash Flows137Notes to the Consolidated Financial Statements139Financial Summary253Definitions and Glossary of Technical Terms254 Company Profile2Corporate Information4Chairman’s Statement7Financial Highlights9Business Highlights11Management Discussion and Analysis13Profiles of Directors and Senior Management60Corporate Governance Report70Directors’ Report95 COMPANY PROFILE OVERVIEW 6I-III We are a clinical-stage novel drug developer in China focusing ondeveloping potential first-in-class/best-in-class drugs. We have sixinnovative potential first-in-class/best-in-class drug candidates atphase I-III clinical stage, and we are committed to becoming a leaderin the research, development and commercialisation of innovativetherapies. Our products aim at tackling the unmet clinical needs andour pipelines cover indications of dermatology such as AGA and acnevulgaris, and indications of tumors. KX-826 •KX-826 KX-826ARKX-826(AGA) KX-826 is an AR antagonist. We are currently developing KX-826 as a potential first-in-class topical drug for the treatment ofandrogenic alopecia (AGA) and acne vulgaris. AR-PROTAC(GT20029) •AR-PROTAC Compound (GT20029) GT20029PROTACAR-PROTACGT20029 GT20029 is a topical AR-PROTAC compound developed bythe Group’s in-house PROTAC platform. We are currentlydeveloping GT20029 for the treatment of AGA and acnevulgaris. (GT0918) •Pruxelutamide (GT0918) (GT0918)ARmCRPCCOVID-19AR+ Pruxelutamide (GT0918) is a second generation AR antagonistwith the potential to be a best-in-class drug. We are currentlydevelopingPruxelutamide for the treatment of mCRPC,COVID-19 and AR+ metastatic breast cancer. GT1708FHedgehog/SMO •GT1708F (Hedgehog/SMO Inhibitor) GT1708FHedgehog/SMOhedgehogGT1708F(IPF) GT1708F(Hedgehog/SMO Inhibitor)is an inhibitor of thehedgehogsignal transduction pathway.We are currentlydeveloping GT1708F primarily for the treatment of idiopathicpulmonary fibrosis (IPF) and blood cancer. GT0486 •GT0486 GT0486PI3K/mTORmTORGT0486(HCC) GT0486 is an inhibitor of the PI3K/mTOR signalling pathwayand a second generation mTOR inhibitor. We are currentlydeveloping GT0486 primarily for the treatment of metastaticsolidtumours such as breast cancer,prostate cancer andhepatocellular carcinoma (HCC). ALK-1(GT90001) •ALK-1 Antibody (GT90001) ALK-12018ALK-1ALK-1HCC ALK-1 antibody is a new anti-angiogenesis inhibitor and targetsa new biological target ALK-1 globally, which we obtained anexclusive global licence from Pfizer in 2018. We are currentlydeveloping ALK-1 antibody for the treatment of metastatic HCCand a variety of solid tumours. CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors 202341420234142023413 Dr. Youzhi Tong(Chairman of the Board and Chief Executive Officer)Dr. Qun Lu (appointed on 14 April 2023)Dr. Xiang Ni (appointed on 14 April 2023)Ms. Yan Lu (resigned on 13 April 2023 Non-executive Directors Mr. Weipeng GaoMs. Geqi WeiMr. Chengwei Liu Independent Non-executive Directors Dr. Michael Min XuMr. Wallace Wai Yim YeungProf. Liang Tong AUDIT COMMITTEE Mr. Wallace Wai Yim Yeung(Chairman)Dr. Michael Min XuMr. Chengwei Liu REMUNERATION COMMITTEE Dr. Michael Min Xu(Chairman)Dr. Youzhi TongProf. Liang Tong NOMINATION COMMITTEE Dr. Youzhi Tong(Chairman)Dr. Michael Min XuMr. Wallace Wai Yim Yeung JOINT COMPANY SECRETARY 20235 122023413 Mr. Ming Ming Cheung (appointed on 12 May 2023)Mr. Wai Chiu WongMs. Yan Lu (resigned on 13 April 2023) AUTHORISED REPRESENTATIVES Dr. Youzhi TongMr. Wai Chiu Wong KINTOR PHARMACEUTICAL LIMITEDANNUAL REPORT 2023 REGISTERED OFFICE Cricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Cricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS IN CHINA 20 No. 20 Songbei RoadSuzhou Industrial ParkSuzhouJiangsuPRC PRINCIPAL PLACE OF BUSINESS IN HONGKONG 202007 Suite 2007, 20th FloorTower 2, The GatewayHarbour CityKowloonHong Kong LEGAL ADVISER 143 Ashurst Hong Kong43/F Jardine House1 Connaught PlaceCentralHong Kong AUDITOR 22 PricewaterhouseCoopersCertified Public Accountants and Registered Public Interest Entity Auditor22/F Prince’s BuildingCentralHong Kong PRINCIPAL SHARE REGISTRAR ANDTRANSFER OFFICE Conyers Trust Company (Cayman) LimitedCricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket SquareHutchins Drive, PO Box 2681Grand Cayman, KY1-1111Cayman Islands HONG KONG SHARE REGISTRAR 183171712–1716 Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong PRINCIPAL BANKS Shanghai Pudong Develop